ABBOTT INDIA LIMITED
🇮🇳India
- Country
- 🇮🇳India
- Ownership
- Private
- Established
- 1888-01-01
- Employees
- 73K
- Market Cap
- $7.5B
- Website
- http://www.abbott.com
Evaluate Safety and Efficacy of ABT-335 in Combination With Atorvastatin in Subjects With Multiple Abnormal Lipid Levels in the Blood
Phase 3
Completed
- Conditions
- Mixed DyslipidemiaCoronary Heart DiseaseDyslipidemia
- Interventions
- First Posted Date
- 2006-03-09
- Last Posted Date
- 2009-06-03
- Lead Sponsor
- Abbott
- Target Recruit Count
- 613
- Registration Number
- NCT00300469
- Locations
- 🇺🇸
Global Medical Information, North Chicago, Illinois, United States
Study to Evaluate the Long-Term Safety and Efficacy of ABT-335, in Combination With Three Different Statins in Subjects With Mixed Dyslipidemia.
Phase 3
Completed
- Conditions
- DyslipidemiaCoronary Heart DiseaseMixed Dyslipidemia
- Interventions
- First Posted Date
- 2006-03-09
- Last Posted Date
- 2009-07-23
- Lead Sponsor
- Abbott
- Target Recruit Count
- 1911
- Registration Number
- NCT00300430
- Locations
- 🇺🇸
Global Medical Information, North Chicago, Illinois, United States
Evaluate Safety and Efficacy of ABT-335 in Combination With Rosuvastatin Calcium in Subjects With Multiple Abnormal Lipid Levels in the Blood
Phase 3
Completed
- Conditions
- DyslipidemiaCoronary Heart DiseaseMixed Dyslipidemia
- Interventions
- First Posted Date
- 2006-03-09
- Last Posted Date
- 2009-06-10
- Lead Sponsor
- Abbott
- Target Recruit Count
- 1445
- Registration Number
- NCT00300482
- Locations
- 🇺🇸
Global Medical Information, North Chicago, Illinois, United States
Evaluate Safety and Efficacy of ABT-335 in Combination With Simvastatin in Subjects With Multiple Abnormal Lipid Levels in the Blood
Phase 3
Completed
- Conditions
- DyslipidemiaCoronary Heart DiseaseMixed Dyslipidemia
- Interventions
- First Posted Date
- 2006-03-09
- Last Posted Date
- 2009-06-03
- Lead Sponsor
- Abbott
- Target Recruit Count
- 657
- Registration Number
- NCT00300456
- Locations
- 🇺🇸
Global Medical Information, North Chicago, Illinois, United States
A Study of Pain Relief in Osteoarthritis
Phase 3
Completed
- Conditions
- Osteoarthritis
- Interventions
- Drug: PlaceboDrug: hydrocodone / acetaminophen extended release
- First Posted Date
- 2006-03-06
- Last Posted Date
- 2011-01-25
- Lead Sponsor
- Abbott
- Target Recruit Count
- 873
- Registration Number
- NCT00298974
- Locations
- 🇺🇸
Site Ref # / Investigator 393, Tucson, Arizona, United States
🇺🇸Site Ref # / Investigator 526, Anaheim, California, United States
🇺🇸Site Ref # / Investigator 721, Los Angeles, California, United States
A Study to Evaluate the Ability of Lupron Depot to Enhance Immune Function Following Bone Marrow Transplantation
Phase 2
Terminated
- Conditions
- Hodgkin DiseaseLymphoma, Non-HodgkinMultiple MyelomaMantle Cell Lymphoma
- Interventions
- Drug: Leuprolide acetate depot (LAD) 11.25 mg 3 MonthDrug: Matched placebo
- First Posted Date
- 2006-01-11
- Last Posted Date
- 2010-05-06
- Lead Sponsor
- Abbott
- Target Recruit Count
- 25
- Registration Number
- NCT00275262
Study of Lopinavir/Ritonavir Tablets Versus Soft Gel Capsules and Once Daily Versus Twice Daily Administration, When Coadministered With Nucleoside Reverse Transcriptase Inhibitors in Antiretroviral Naive Human Immunodeficiency Virus Type 1 Infected Subjects
Phase 3
Completed
- Conditions
- Human Immunodeficiency Virus Infections
- Interventions
- Drug: lopinavir/ritonavir (LPV/r) (tablet or capsule) with nucleoside reverse transcriptase inhibitors (NRTIs)
- First Posted Date
- 2005-12-07
- Last Posted Date
- 2012-02-06
- Lead Sponsor
- Abbott
- Target Recruit Count
- 664
- Registration Number
- NCT00262522
- Locations
- 🇺🇸
Site Reference ID/Investigator# 872, Fountain Valley, California, United States
🇺🇸Site Reference ID/Investigator# 845, Safety Harbor, Florida, United States
🇺🇸Site Reference ID/Investigator# 1155, Dallas, Texas, United States
A Study of Sibutramine in Overweight Adolescents to Assess Weight Loss and Safety.
Phase 3
Completed
- Conditions
- Obesity
- First Posted Date
- 2005-12-06
- Last Posted Date
- 2007-08-31
- Lead Sponsor
- Abbott
- Target Recruit Count
- 498
- Registration Number
- NCT00261911
A Study of Zemplar® Injection and Hectorol® Injection on Intestinal Absorption of Calcium in Chronic Kidney Disease
Phase 4
Completed
- Conditions
- Chronic Kidney Disease, Stage 5Secondary Hyperparathyroidism
- Interventions
- First Posted Date
- 2005-11-24
- Last Posted Date
- 2009-12-24
- Lead Sponsor
- Abbott
- Target Recruit Count
- 41
- Registration Number
- NCT00257920
Efficacy and Safety of Adalimumab in Subjects With Moderate to Severe Chronic Plaque Psoriasis
Phase 3
Completed
- Conditions
- Psoriasis
- First Posted Date
- 2005-10-13
- Last Posted Date
- 2007-08-29
- Lead Sponsor
- Abbott
- Target Recruit Count
- 1212
- Registration Number
- NCT00237887
© Copyright 2025. All Rights Reserved by MedPath